Hormone-refractory prostate cancer
Not recruitingStudy Comparing Docetaxel Alone and Docetaxel with Radium-223 for Patients with Metastatic Castration-Resistant Prostate Cancer
Study Comparing Docetaxel Alone and Docetaxel with Radium-223 for Patients with Metastatic Castration-Resistant Prostate Cancer
- Disease:Hormone-refractory prostate cancer
- Substances:Radium RA 223 dichloride
Spain- Participants:18–64 years · 65+ years
- Substances:Radium RA 223 dichloride
- Sponsor:Memorial Sloan Kettering Cancer Center











